Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda | Zendy

Emmanuel Ndashimye | Zendy; Mariano Avino | Zendy; Abayomi S Olabode | Zendy; Art F. Y. Poon | Zendy; Richard M. Gibson | Zendy; Yue Li | Zendy; Adam Meadows | Zendy; Christine Tan | Zendy; Paul S Reyes | Zendy; Cissy Kityo | Zendy; Fred Kyeyune | Zendy; Immaculate Nankya | Zendy; Miguel E. QuiñonesMateu | Zendy; Eric J. Arts | Zendy

Open Access

Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda

Author(s) -

Emmanuel Ndashimye,

Mariano Avino,

Abayomi S Olabode,

Art F. Y. Poon,

Richard M. Gibson,

Yue Li,

Adam Meadows,

Christine Tan,

Paul S Reyes,

Cissy Kityo,

Fred Kyeyune,

Immaculate Nankya,

Miguel E. QuiñonesMateu,

Eric J. Arts

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa355

Subject(s) - raltegravir , dolutegravir , integrase inhibitor , integrase , virology , drug resistance , human immunodeficiency virus (hiv) , medicine , biology , lentivirus , antiretroviral therapy , genetics , viral load , viral disease

Increasing first-line treatment failures in low- and middle-income countries (LMICs) have led to increased use of integrase strand transfer inhibitors (INSTIs) such as dolutegravir. However, HIV-1 susceptibility to INSTIs in LMICs, especially with previous raltegravir exposure, is poorly understood due to infrequent reporting of INSTI failures and testing for INSTI drug resistance mutations (DRMs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research